Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 9;19(1):2206278. doi: 10.1080/21645515.2023.2206278

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

PMC Copyright notice

Figure 1. — Flow diagram of study participants.

One hundred and thirty-six patients with neuromuscular diseases (NMDs) were screened from the patient registry. Fifty-two patients were invited to complete the hesitancy survey arm, and 48 patients were invited to join the reactogenicity and immunogenicity arm of the study. Forty-five patients completed the first hesitancy survey, and 41 (91.1%) of them completed both first and second surveys. For the reactogenicity and immunogenicity arm of the study, 22 patients joined and 17 were inoculated with BNT162b2 or CoronaVac at our University of Hong Kong (HKU) Community Vaccination Centers (CVCs) research site. These patients recorded adverse reactions in a 7-day diary system after vaccination for reactogenicity/safety analyses and had blood sampling. Additionally, five patients who received two doses of CoronaVac at nearby CVCs and had blood sampling after the second dose. Reactogenicity and immunogenicity data from healthy children and adolescents (n = 280) used for comparisons with patients with NMDs were retrieved from our previous publication.²⁷ CVCs = Community Vaccination Centers research site, NMDs = patients with neuromuscular diseases, COVAC = Coronavirus disease-19 (COVID-19) Vaccination in Adolescents and Children, HKU = University of Hong Kong. B, 1 dose of BNT162b2; BB, 2 doses of BNT162b2; C, 1 dose of CoronaVac; CC, 2 doses of CoronaVac; BBB, 3 dose of BNT162b2; CCC, 3 doses of CoronaVac; CCB, 2 doses of CoronaVac and 1 dose of BNT162b2.